> ivermectin does not provide clinically meaningful benefits for treating COVID-19 in a largely vaccinated population.

Why is the scope limited to vaccinated population?

Different studies have different scopes, recent studies in G20 countries are essentially trials in largely vaccinated populations.

These are also trials in regions with relatively low rates of parasitic worm infection.

The early meta studies looked at trials in poorer regions of non G20 countries and showed the benefits of killing parasitic worms as increased resistance to flu, COVID, etc, etc across the board. Post worm dosing survival rates for most things increased compared to regions that didn't receive dosing.

These early studies are the main reason we see results such as the graph in a peer comment - killing worms improves COVID survival for those that had worm infestations to begin with.

Neither of the referenced studies note when the treatment started; one states "plus standard NHS treatment", which implies presentation at a hostpital -- usually days after onset of symptoms.

Virtually all of the studies that do indicate treatment initiation within 1-3 days of onset of symptoms do strongly indicate effectiveness.

It seems ... odd to avoid disclosing average start of treatment from onset of symptoms, don't you think? Especially when this appears to be the primary determinant of successful treatment in numerous (>100) studies?

See: https://c19ivm.org/meta.html

Here's a graph of onset of treatment vs. therapeutic effectiveness: https://c19ivm.org/mr/mr-all-delay.svg

Literally linearly from 100% efficacy to 0% efficacy over 7 days from onset of symptoms. Linear, over ~100 studies!

You don't see that kind of statistically profound predictive accuracy often; but when you do, you sit up and take notice.

Furthermore, in various other anti-viral treatments that are considered effective, onset-of-treatment is a critical determinant. Typically, over 24 to 48 hours after onset, treatment is pointless.

Why not consider that important to address (or even mention?) in Ivermectin studies? The mind boggles...

The new article cited states that in the 1432 people who took part of the trial the folks that took ivermectin recovered one day faster than the folks who did not (11 vs 12 days).

Thus there is a small effect seen that is indeed suggestive that ivermectin helped. However there are a number of things to call into question including why didn't they just take the medicine for longer than 6 days and most antivirals will not show that significant of an impact in this type of study.

Another study showed that ivermectin synergized with remdesivir making each drug approximately 4 to 6 times more effective. As with most viruses I would expect a cocktail or combo antiviral to be much more effective than monotherapy. Is therefore not that surprising that many of these ivermectin trials do not seem to discover much of an effect against COVID